{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:09:14Z","timestamp":1792001354462,"version":"4.4.0"},"reference-count":70,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cholestatic liver diseases such as Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) cause significant morbidity and mortality. Chronic pruritus is common, debilitating, and impairs health\u2010related quality of life. Recently, pharmacological inhibition of the ileal bile acid transporter (IBAT) has emerged as a therapeutic target.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To review the current landscape of IBAT inhibitors, summarise emerging clinical data, discuss their role in the treatment of cholestatic liver diseases and future directions for their development and use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This narrative review summarises current data on IBAT inhibitors, exploring their mechanisms, efficacy, and safety across ALGS, PFIC, PBC and PSC. References were identified through searches of PubMed from January 2000 to August 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In phase 2 and 3 trials involving paediatric patients with ALGS and PFIC, IBAT inhibitors (odevixibat and maralixibat) significantly reduced pruritus and serum bile acid concentrations. In post hoc analysis, responders demonstrated improved event\u2010free and transplant\u2010free survival compared to historic control cohorts. The phase 3 trial of linerixibat in PBC demonstrated an improvement in pruritus compared to placebo. Mild to moderate gastrointestinal side effects, most commonly diarrhoea and abdominal discomfort, are common with IBAT inhibition, particularly in PBC and PSC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IBAT inhibitors represent the first upstream pharmacotherapy targeting enterohepatic bile acid recirculation and are effective at reducing pruritus in ALGS and PFIC. Their role in PBC and PSC is promising yet undefined. Long\u2010term studies are needed to assess effects on fibrosis progression, hepatocellular carcinoma risk and transplant\u2010free survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/apt.70666","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T08:59:31Z","timestamp":1775725171000},"page":"6-22","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Review Article: Ileal Bile Acid Transport (\n                    <scp>IBAT<\/scp>\n                    ) Inhibitors as an Emerging Treatment for Cholestatic Liver Disease"],"prefix":"10.1111","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0136-6699","authenticated-orcid":false,"given":"Matthew","family":"Peverelle","sequence":"first","affiliation":[{"name":"Department of Gastroenterology Monash Health  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8201-8182","authenticated-orcid":false,"given":"Samantha M. A.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Institute of Liver Studies King's College Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Peverelle","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology Monash Health  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0472-9686","authenticated-orcid":false,"given":"Sital","family":"Shah","sequence":"additional","affiliation":[{"name":"Institute of Liver Studies King's College Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Greener","sequence":"additional","affiliation":[{"name":"Institute of Liver Studies King's College Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9547-2809","authenticated-orcid":false,"given":"Deepak","family":"Joshi","sequence":"additional","affiliation":[{"name":"Institute of Liver Studies King's College Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0344-0218","authenticated-orcid":false,"given":"Jeremy S.","family":"Nayagam","sequence":"additional","affiliation":[{"name":"Institute of Liver Studies King's College Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29019"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.02.007"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21185"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13449"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00054.2017"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14553"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(21)01256\u20103"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(22)00093\u20100"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(25)00192\u2010X"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(24)00074\u20108"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000153"},{"key":"e_1_2_14_13_1","unstructured":"Mirum Pharmaceuticals Inc \u201cA Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) \u201d(2025) https:\/\/clinicaltrials.gov\/study\/NCT04663308."},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1980"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000502"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000727"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001958"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1244"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl\u20102024\u2010BASL.31"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(17)30319\u20107"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1305"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.10.032"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2022.03.002"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2018.06.003"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.12.007"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15271"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2016.05.006"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620\u2010023\u201008050\u20109"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.639674"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.04.032"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27240"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002862"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575\u2010022\u201000687\u20107"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.006"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.15\u20104\u2010351"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32117"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32771"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000703"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M306370200"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.8012.1"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.09.055"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00178.2014"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01072128"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102036.2011.04675.x"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(18)30123\u20107"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00931"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100573"},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2024.2336986"},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000376"},{"key":"e_1_2_14_50_1","unstructured":"Albireo an Ipsen Company \u201cAn Open Label Phase 2 Study to Evaluate the Effect of A3907 on Safety Tolerability Pharmacokinetics and Pharmacodynamics in Adults With Primary Sclerosing Cholangitis (PSC) \u201d(2025) https:\/\/clinicaltrials.gov\/study\/NCT05642468."},{"key":"e_1_2_14_51_1","unstructured":"Drugs.com \u201cLivmarli (Maralixibat) FDA Approval History \u201d(2025) https:\/\/www.drugs.com\/history\/livmarli.html."},{"key":"e_1_2_14_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2011.181"},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16201"},{"key":"e_1_2_14_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2018.07.010"},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.12.013"},{"key":"e_1_2_14_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010022\u201002261\u20108"},{"key":"e_1_2_14_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100782"},{"key":"e_1_2_14_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(24)00080\u20103"},{"key":"e_1_2_14_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.022"},{"key":"e_1_2_14_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306185"},{"key":"e_1_2_14_61_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312100"},{"key":"e_1_2_14_62_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714519"},{"key":"e_1_2_14_63_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.10.001"},{"key":"e_1_2_14_64_1","volume-title":"Due to Risk of Serious Liver Injury, FDA Restricts Use of Ocaliva (Obeticholic Acid) in Primary Biliary Cholangitis (PBC) Patients With Advanced Cirrhosis","author":"Center for Drug Evaluation and Research","year":"2026"},{"key":"e_1_2_14_65_1","unstructured":"European Medicines Agency \u201cRevocation of Conditional Marketing Authorisation for Ocaliva \u201d(2024)."},{"key":"e_1_2_14_66_1","volume-title":"Serious Liver Injury Being Observed in Patients Without Cirrhosis Taking Ocaliva (Obeticholic Acid) to Treat Primary Biliary Cholangitis","author":"Center for Drug Evaluation and Research","year":"2024"},{"key":"e_1_2_14_67_1","unstructured":"Mirum Pharmaceuticals Inc \u201cA Randomized Double\u2010Blind Placebo\u2010Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Biliary Cholangitis \u201d(2026) https:\/\/clinicaltrials.gov\/study\/NCT05050136."},{"key":"e_1_2_14_68_1","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro\u20102025\u2010103215"},{"key":"e_1_2_14_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.05.018"},{"key":"e_1_2_14_70_1","unstructured":"L.Wium \u201cIleal Bile Acid Transport Inhibitors for Intrahepatic Cholestasis of Pregnancy: A Case Report \u201d(2024) https:\/\/isom\u2010somanz2024.org\/ileal\u2010bile\u2010acid\u2010transport\u2010inhibitors\u2010for\u2010intrahepatic\u2010cholestasis\u2010of\u2010pregnancy\u2010a\u2010case\u2010report\/."},{"key":"e_1_2_14_71_1","unstructured":"Mirum Pharmaceuticals Inc \u201cA Phase 2a\/2b Randomized Double\u2010Blind Placebo\u2010Controlled Study to Evaluate the Efficacy and Safety of Volixibat in Adult Women With Intrahepatic Cholestasis of Pregnancy and Elevated Serum Bile Acid Concentrations (OHANA) \u201d(2024) https:\/\/clinicaltrials.gov\/study\/NCT04718961."}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.70666","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/apt.70666","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.70666","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T13:11:09Z","timestamp":1781097069000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.70666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1111\/apt.70666"],"URL":"https:\/\/doi.org\/10.1111\/apt.70666","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"2025-12-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}